Posts

The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday estimated that nearly 13% of the circulating coronavirus variants in the United States were of the BA.4.6 subvariant of Omicron, as of the week ended Oct. 1.

Moderna Inc. has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.

Around two-thirds of adults in the United States do not plan to get updated COVID-19 booster shots soon, according to a survey conducted by the Kaiser Family Foundation (KFF), a health policy nonprofit organization.

As it gears up to launch several new products in the coming months, Moderna has created a new leadership role and onboarded an industry veteran, the company announced Thursday.

Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.

The agency had earlier said Moderna requested authorization for additional batches in light of the current supply issues. It did not provide details on the number of doses cleared.

Pfizer Inc. and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration’s authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years.

The French drugmaker is in talks with a potential partner on producing an updated version of its COVID-19 vaccine that targets new variants of the disease, sending its shares up. Valneva has struggled to bring its COVID-19 vaccine to market to compete with rival products from drugmakers such as AstraZeneca, Moderna and BioNTech/Pfizer.

As of Thursday, 4.4 million people had received redesigned COVID-19 booster shots, a few weeks into the government’s new vaccination campaign.

The U.S. Centers for Disease Control and Prevention expects COVID-19 vaccine boosters targeting circulating variants of the virus to be available for children aged 5-11 years by mid-October.